ARTICLE | Clinical News
LY2228820: Phase I data
May 28, 2012 7:00 AM UTC
An open-label, dose-escalation, U.S. Phase I trial in 54 patients with advanced cancer showed that LY2228820 produced 15 cases of stable disease. The maximum tolerated dose (MTD) was twice-daily 420 m...